Literature DB >> 18992380

Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios.

Eugenio Suárez1, Jennifer S Smith, F Xavier Bosch, Pekka Nieminen, Chien-Jen Chen, Saku Torvinen, Nadia Demarteau, Baudouin Standaert.   

Abstract

Mathematical models provide valuable insights into the public health and economic impact of cervical cancer vaccination programmes. An in-depth economic analysis should explore the effects of different vaccine-related factors and vaccination scenarios (independent of screening practices) on health benefits and costs. In this analysis, a Markov cohort model was used to explore the impact of vaccine characteristics (e.g. cross-type protection and waning of immunity) and different vaccination scenarios (e.g. age at vaccination and multiple cohort strategies) on the cost-effectiveness results of cervical cancer vaccination programmes. The analysis was applied across different regions in the world (Chile, Finland, Ireland, Poland and Taiwan) to describe the influence of location-specific conditions. The results indicate that in all the different settings cervical cancer vaccination becomes more cost-effective with broader and sustained vaccine protection, with vaccination at younger ages, and with the inclusion of several cohorts. When other factors were varied, the cost-effectiveness of vaccination was most negatively impacted by increasing the discount rate applied to costs and health effects.

Entities:  

Mesh:

Year:  2008        PMID: 18992380     DOI: 10.1016/j.vaccine.2008.05.069

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  22 in total

1.  Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program.

Authors:  Nadia Demarteau; Thomas Breuer; Baudouin Standaert
Journal:  Pharmacoeconomics       Date:  2012-04       Impact factor: 4.981

2.  Calibrating models in economic evaluation: a seven-step approach.

Authors:  Tazio Vanni; Jonathan Karnon; Jason Madan; Richard G White; W John Edmunds; Anna M Foss; Rosa Legood
Journal:  Pharmacoeconomics       Date:  2011-01       Impact factor: 4.981

3.  Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore.

Authors:  Sun Kuie Tay; Bee-Wah Lee; Woo Yun Sohn; I-Heng Lee; Gaurav Mathur; Melvin Sanicas; Georges Van Kriekinge
Journal:  Singapore Med J       Date:  2017-10-06       Impact factor: 1.858

Review 4.  The cost effectiveness of human papillomavirus vaccines: a systematic review.

Authors:  Katherine Seto; Fawziah Marra; Adam Raymakers; Carlo A Marra
Journal:  Drugs       Date:  2012-03-26       Impact factor: 11.431

5.  A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer.

Authors:  Nadia Demarteau; Bruno Detournay; Bertrand Tehard; Abdelkader El Hasnaoui; Baudouin Standaert
Journal:  Int J Public Health       Date:  2010-11-26       Impact factor: 3.380

6.  Cost-effectiveness of different human papillomavirus vaccines in Singapore.

Authors:  Vernon J Lee; Sun Kuie Tay; Yee Leong Teoh; Mei Yin Tok
Journal:  BMC Public Health       Date:  2011-03-31       Impact factor: 3.295

7.  Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system.

Authors:  I H-I Chow; C-H Tang; S-L You; C-H Liao; T-Y Chu; C-J Chen; C-A Chen; R-F Pwu
Journal:  Br J Cancer       Date:  2010-11-23       Impact factor: 7.640

8.  Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies.

Authors:  Laureen Ribassin-Majed; Rachid Lounes; Stephan Clémençon
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

9.  Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.

Authors:  Michele Kohli; Donna Lawrence; Jennifer Haig; Andrea Anonychuk; Nadia Demarteau
Journal:  BMC Public Health       Date:  2012-10-13       Impact factor: 3.295

Review 10.  Human papillomavirus vaccination in low-resource countries: lack of evidence to support vaccinating sexually active women.

Authors:  V Tsu; M Murray; S Franceschi
Journal:  Br J Cancer       Date:  2012-09-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.